| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Bacterial cell wall or membrane components in Gram-positive pathogens. Antibiofilm agent-1 targets essential components in Gram-positive bacteria, leading to growth inhibition. While the precise molecular target is not specified in the available literature, its activity is characterized by its ability to inhibit the growth of Gram-positive pathogens and prevent biofilm formation. Biofilms are communities of bacteria encased in an extracellular matrix that protect them from environmental stresses and antibiotics. This compound interferes with this protective mechanism.
|
|---|---|
| ln Vitro |
In vitro, Antibiofilm agent-1 exhibits antibacterial activity against Gram-positive pathogens. It inhibits bacterial growth, as demonstrated in standard antimicrobial susceptibility tests (e.g., broth microdilution) with minimum inhibitory concentration (MIC) values determined. It is also assessed for its ability to prevent biofilm formation in vitro, typically using crystal violet staining or confocal microscopy to quantify biofilm biomass. The compound's efficacy is compared to standard antibiotics. It is effective against a range of Gram-positive species.
|
| ln Vivo |
In vivo activity data for Antibiofilm agent-1 are not detailed in the available literature. As a research compound, its primary characterization appears to be in vitro. The compound is an antibacterial agent against Gram-positive pathogens, suggesting potential for in vivo efficacy in animal models of infection. However, specific in vivo studies, including animal model efficacy, pharmacokinetics, or toxicity, have not been reported in the available sources. Further investigation is required to establish its in vivo profile.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Antibiofilm agent-1 as its mechanism involves antibacterial activity rather than a specific enzyme target. Standard antimicrobial susceptibility testing is used to characterize this compound. The broth microdilution method is employed to determine the Minimum Inhibitory Concentration (MIC) against Gram-positive pathogens. The bacteria are cultured in Mueller-Hinton broth, and serial dilutions of the compound are added. After incubation, the MIC is determined as the lowest concentration that inhibits visible bacterial growth. Biofilm formation assays use crystal violet staining.
|
| Cell Assay |
In vitro cell-based assays for Antibiofilm agent-1 are performed using bacterial cell cultures, not mammalian cells. Gram-positive bacterial strains (e.g., Staphylococcus aureus, Bacillus subtilis) are cultured in appropriate media. The compound is added at various concentrations, and bacterial growth is monitored by measuring optical density (OD600). Biofilm formation is assessed in 96-well plates, where bacteria are allowed to form biofilms in the presence or absence of the compound. After incubation, the biofilm is stained with crystal violet, and the absorbance is measured. These assays determine the antibacterial and antibiofilm efficacy.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for Antibiofilm agent-1 are not described in the available literature. As a research compound, its in vivo profile has not been extensively published. If in vivo studies were conducted, they would likely involve murine models of infection, such as a subcutaneous or systemic infection model with Gram-positive pathogens. Infected animals would be treated with the compound, and bacterial load in tissues, survival, and clinical signs would be monitored. However, no such studies are reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Antibiofilm agent-1 have not been reported in the available literature. The compound is a solid at room temperature. It is soluble in DMSO at concentrations up to approximately 100 mg/mL. Its molecular weight is 413.88. Its stability, half-life, and bioavailability are unknown. As a research compound, its PK profile has not been characterized. Appropriate handling and storage conditions are recommended based on its chemical properties.
|
| Toxicity/Toxicokinetics |
Toxicological data for Antibiofilm agent-1 are not detailed in the available literature. It is a research compound not intended for human use. No LD50 values or repeated-dose toxicity studies have been reported. Standard safety pharmacology studies have not been performed. As with all research chemicals, appropriate safety precautions should be taken when handling. Its specific toxicological profile has not been established.
|
| References | |
| Additional Infomation |
Antibiofilm agent-1 is an antibacterial agent that inhibits the growth of Gram-positive pathogens, as detailed in patent WO2017011725A1 (compound 17). Its molecular formula is C11H5Br2Cl2NO2, and its molecular weight is 413.88. It is designed to prevent or disrupt biofilm formation. It is available for research use only and is not clinically approved.
|
| Exact Mass |
412.804
|
|---|---|
| CAS # |
2001602-10-2
|
| PubChem CID |
126481602
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=C(C=C(C(=C1C(=O)C2=CC(=C(N2)Br)Br)O)Cl)Cl
|
| InChi Key |
IJADFNLHNSFJDN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H5Br2Cl2NO2/c12-6-3-8(16-11(6)13)10(18)5-1-4(14)2-7(15)9(5)17/h1-3,16-17H
|
| Chemical Name |
(4,5-dibromo-1H-pyrrol-2-yl)-(3,5-dichloro-2-hydroxyphenyl)methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~100 mg/mL (~241.62 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
